To ensure vaccines reach all the world’s children, Gavi, is inviting entrepreneurs and businesses to identify innovations in vaccine delivery by applying to its INFUSE initiative.
With global immunisation coverage stalled at around 80% for several years and 19 million children missing out on a full course of basic vaccines, Gavi launched INFUSE – Innovation for Uptake, Scale and Equity in Immunisation – in 2016. This aims to find new thinking and technology that will help modernise often outdated vaccine delivery systems and then accelerate the expansion of these solutions.
“The speed with which the disease outbreaks disrupt the lives of children in the world’s poorest countries is only getting faster. We need to keep up and find new innovative solutions to evolving challenges and gaps in immunisation coverage which affect the most vulnerable children”, said Managing Director of resource mobilisation and private sector partnerships Marie-Ange Saraka-Yao.
“To create these solutions, we started INFUSE. This platform brings together global problem solvers who can find new ways to accelerate immunisation coverage and reduce inequities in access to vaccination for the world’s poorest children.”
Following last year’s launch at the World Economic Forum Annual Meeting in Davos, Gavi has already helped one of INFUSE’s initial pacesetters, Nexleaf Analytics, forge a partnership with Google.org. Together these two companies are working to provide real-time data solutions to keep vaccines cold and safe in developing countries.
“INFUSE has been key to helping Nexleaf bring our data-driven technology to the next level”, said Nexleaf’s CTO and Co-Founder Dr. Martin Lukac. “Becoming an INFUSE pacesetter not only allowed us to connect with a global community of innovators, it also helped us access the financial and technical support we need to take our technology forward, to improve vaccine cold chains in low-income countries, and to significantly increase our impact”.
For INFUSE 2017, Gavi welcomes proposals for projects that are already operating in Gavi-supported countries or have completed their pilot phase and offer a strong evidence base. The Vaccine Alliance will identify the most promising innovations and connect them with influential public and private sector leaders.